Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Jazz Pharmaceuticals (JAZZ) and Talkspace (TALK)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zevra Therapeutics (ZVRA – Research Report), Jazz Pharmaceuticals (JAZZ – Research Report) and Talkspace (TALK – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zevra Therapeutics (ZVRA)
In a report released today, Lachlan Hanbury Brown from William Blair maintained a Buy rating on Zevra Therapeutics. The company’s shares closed last Monday at $9.12, close to its 52-week high of $9.76.
According to TipRanks.com, Brown is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zevra Therapeutics with a $24.67 average price target.
See the top stocks recommended by analysts >>
Jazz Pharmaceuticals (JAZZ)
In a report released today, Etzer Darout from Barclays maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $224.00. The company’s shares closed last Monday at $185.40.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $229.55, implying a 27.6% upside from current levels. In a report issued on February 25, TipRanks – OpenAI also upgraded the stock to Buy with a $191.00 price target.
Talkspace (TALK)
In a report released today, Scott Schoenhaus from KeyBanc maintained a Hold rating on Talkspace. The company’s shares closed last Monday at $5.12.
According to TipRanks.com, Schoenhaus is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Talkspace is a Moderate Buy with an average price target of $6.21, implying a 20.6% upside from current levels. In a report released yesterday, William Blair also downgraded the stock to Hold with a $4.76 price target.
